ABVXAbivax S.A.
The schedule
- Tue9Feb
- Tue11May
- Tue10Aug
- Tue9Nov
Past
- Mon22Jun
Actual outcome: Bear · $96.15 at outcome
Abivax reported Q1 2026 earnings that exactly matched analyst estimates with an EPS of -2.1. Despite the in-line financial results, the stock experienced a bearish reaction due to the announcement that the Schall Law Firm launched an investigation into the company for potential securities law violations. This sudden legal scrutiny and the threat of potential litigation drove negative investor sentiment and a subsequent sell-off.
Abivax reported Q1 2026 earnings that exactly matched analyst estimates with an EPS of -2.1. Despite the in-line financial results, the stock experienced a bearish reaction due to the announcement that the Schall Law Firm launched an investigation into the company for potential securities law violations. This sudden legal scrutiny and the threat of potential litigation drove negative investor sentiment and a subsequent sell-off.
- Thu11Jun
Actual outcome: Bull · $127.91 at outcome
Abivax reported in-line EPS of -$2.10 and provided updated cash runway guidance following the Phase 3 ABTECT trial readout for obefazimod in ulcerative colitis. Although the initial data release in early June sparked a sell-off and law firm investigations due to safety concerns over unrelated cancer cases, the drug's strong efficacy—meeting all primary and key secondary endpoints—ultimately overshadowed these fears. The market prioritized the positive clinical efficacy and the company's stabilized funding outlook, driving the stock to close at $101.66, well above the $65 bull target.
Abivax reported in-line EPS of -$2.10 and provided updated cash runway guidance following the Phase 3 ABTECT trial readout for obefazimod in ulcerative colitis. Although the initial data release in early June sparked a sell-off and law firm investigations due to safety concerns over unrelated cancer cases, the drug's strong efficacy—meeting all primary and key secondary endpoints—ultimately overshadowed these fears. The market prioritized the positive clinical efficacy and the company's stabilized funding outlook, driving the stock to close at $101.66, well above the $65 bull target.
- Tue2Jun
Actual outcome: Bull · $144.65 at outcome
Abivax shares rallied following the release of positive top-line data from its Phase 3 trial evaluating Obefazimod for ulcerative colitis. The stock moved higher because the successful clinical results validated the treatment's efficacy, allowing investors to look past a series of ongoing shareholder rights investigations and focus on the drug's path to regulatory approval.
Abivax shares rallied following the release of positive top-line data from its Phase 3 trial evaluating Obefazimod for ulcerative colitis. The stock moved higher because the successful clinical results validated the treatment's efficacy, allowing investors to look past a series of ongoing shareholder rights investigations and focus on the drug's path to regulatory approval.
